TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC
2023 · Biology Direct · 31 citations
https://doi.org/10.1186/s13062-023-00376-8
B
Bo Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
23
Papers
239
Citations
9
h-index
9
i10-index
Bo Li is an academic researcher from Ningxia Medical University. The author has contributed to research in topics: Sepsis Diagnosis and Treatment & RNA modifications and cancer & Chronic Kidney Disease and Diabetes. The author has an h-index of 9, co-authored 20 publications.
ORCID: 0000-0002-9731-2814Papers by this author
worksClinical predictors for nondiabetic kidney diseases in patients with type 2 diabetes mellitus: a retrospective study from 2017 to 2021
2022 · BMC Endocrine Disorders · 20 citations
https://doi.org/10.1186/s12902-022-01082-8
The UDPase ENTPD5 regulates ER stress-associated renal injury by mediating protein N-glycosylation
2023 · Cell Death and Disease · 19 citations
https://doi.org/10.1038/s41419-023-05685-4
Uplift modeling to predict individual treatment effects of renal replacement therapy in sepsis-associated acute kidney injury patients
2024 · Scientific Reports · 5 citations
https://doi.org/10.1038/s41598-024-55653-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat